Sam is a Partner with 7G Bioventures and is a venture capital deal professional with a broad network and direct experience investing in, serving on the boards of, and otherwise supporting over 25 biotech and medical device startup companies. Prior to 7G Bioventures, Sam was a  Managing Director with MedImmune Ventures and a Principal with SV Life Sciences. He has also served as Chief Business Officer and Chief Medical Officer for CyanVac LLC.

Before his venture capital career, Sam was a management consultant with McKinsey & Company, leading teams that advised pharmaceutical and medical device clients in corporate finance, commercialization and portfolio strategy.

Sam received his MD and PhD in Biochemistry from Stanford University and a BA in Biochemistry from Harvard University.

Sam serves or has served as a board member or observer for Applied Genetic Technologies (NASDAQ: AGTC), Ocular Therapeutix (NASDAQ: OCUL), Confluent Surgical (acquired by Tyco), Sapphire (acquired by Helsinn), and Mesentech.